Sayre Therapeutics today announced the establishment of a Named Patient Program forDaunoXome® (liposomal daunorubicin) for India, Sri Lanka, Bangladesh, Nepal and Pakistan, under an exclusive distribution arrangement with Galen Limited. DaunoXome® is an anti-cancer medicine (a cytotoxic agent) that belongs to a group of medicines called anthracyclines. A Named Patient Program is a mechanism through which physicians can legally and ethically prescribe drugs which are not yet approved in a specific country, in line with local country regulations.